Please login to the form below
hypoglycaemia
This page shows the latest hypoglycaemia news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk spends $800m on biotech and 'glucose responsive insulin' tech
Combining this technology with Novo Nordisk’s insulin to create GRIs would ultimately help further its goal of eliminating the risk of hypoglycaemia, the main risk associated with insulin therapy. ... have the potential to lead to the development of
Latest news
-
FDA starts review of Sanofi’s oral type 1 diabetes drug
The results suggest adding the drug to insulin therapy can improve glucose control as measured by haemoglobin A1c levels, with a reduced risk of potentially dangerous low blood sugar levels (hypoglycaemia).
-
Novo says real-world data backs its insulin switching
Rates of overall hypoglycaemia were also significantly lower after switching to Tresiba, falling 85% in type 1 and 92% in type 2 patients at six months. ... compare the two drugs on not only glucose control and hypoglycaemia but also cardiovascular
-
Novo Nordisk's long-acting haemophilia B drug cleared by FDA
likely to cause low blood sugar levels or hypoglycaemia in patients with type 2 diabetes compared to Sanofi's Lantus.
-
Novo seeks to strengthen Tresiba label in US
An earlier study - called SWITCH 2 - also found an advantage for Tresiba over Lantus on hypoglycaemia rates. ... The risk of severe hypoglycaemia is a major cause for people with type 2 diabetes not reaching their treatment targets," said Mads Krogsgaard
-
AstraZeneca's Forxiga set to be recommended by NICE
dose in combination with either metformin or insulin for patients unable to take sulphonylurea medicines or at significant risk of hypoglycaemia.
More from news
Approximately 2 fully matching, plus 94 partially matching documents found.
Latest Intelligence
-
Interview: Peter Meeus, Novo Nordisk
end of last year and has demonstrated it is as effective in reducing blood glucose levels as is its rival Lantus from Sanofi, yet carries less risk of hypoglycaemia. ... In addition, Meeus highlighted a need to raise awareness among the healthcare
-
Interview: Pierre Chancel, Sanofi Diabetes
2 diabetes further reduce HbA1c, with the benefit of weight loss and limited risk of hypoglycaemia.”.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
How technology is shaping patient education
The simulation showed the high impact of mild hypoglycaemia (low blood sugar) on a patient; it made the viewer ‘ feel’ the symptoms of hypoglycaemia in various scenarios through a typical day
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Scientific Director
-
Highly Competitive Salary &Benefits
- Account Manager, Healthcare Advertising
-
Salary TBC
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
- Director Healthcare PR Communications
-
Salary TBC
-
Account Director
-
Negotiable
-
Account Director - Digital
-
Great salary and benefits
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Experienced Editor, London, Medical Communications
-
Competitive package
- Account Director – Global Healthcare PR
-
Salary TBC
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Associate Medical Director
-
Highly Competitive
-
Associate Medical Director
-
Salary TBC
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Scientific Team Lead
-
Competitive Salary
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
Subscribe to our email news alerts
PMHub
Apex.co.uk Conferences, Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...
Latest intelligence
- Retaining reader value in plain language summaries of clinical studies
- Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
- Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
- Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
- Making Europe a leader in bioscience: boosting trust and opening minds
- A vision of Paris as Europe’s leading hub for life sciences innovation...
Quick links
Infographics
